Cargando…

Drug Candidates for Autoimmune Diseases

Most of the immunosuppressive drugs used in the clinic to prevent organ rejection or to treat autoimmune disorders were originally isolated from fungi or bacteria. Therefore, in addition to plants, these are valuable sources for identification of new potent drugs. Many side effects of established dr...

Descripción completa

Detalles Bibliográficos
Autores principales: Saurin, Sabrina, Meineck, Myriam, Erkel, Gerhard, Opatz, Till, Weinmann-Menke, Julia, Pautz, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143092/
https://www.ncbi.nlm.nih.gov/pubmed/35631330
http://dx.doi.org/10.3390/ph15050503
_version_ 1784715720511193088
author Saurin, Sabrina
Meineck, Myriam
Erkel, Gerhard
Opatz, Till
Weinmann-Menke, Julia
Pautz, Andrea
author_facet Saurin, Sabrina
Meineck, Myriam
Erkel, Gerhard
Opatz, Till
Weinmann-Menke, Julia
Pautz, Andrea
author_sort Saurin, Sabrina
collection PubMed
description Most of the immunosuppressive drugs used in the clinic to prevent organ rejection or to treat autoimmune disorders were originally isolated from fungi or bacteria. Therefore, in addition to plants, these are valuable sources for identification of new potent drugs. Many side effects of established drugs limit their usage and make the identification of new immunosuppressants necessary. In this review, we present a comprehensive overview of natural products with potent anti-inflammatory activities that have been tested successfully in different models of chronic inflammatory autoimmune diseases. Some of these candidates already have passed first clinical trials. The anti-inflammatory potency of these natural products was often comparable to those of established drugs, and they could be used at least in addition to standard therapy to reduce their dose to minimize unwanted side effects. A frequent mode of action is the inhibition of classical inflammatory signaling pathways, such as NF-κB, in combination with downregulation of oxidative stress. A drawback for the therapeutic use of those natural products is their moderate bioavailability, which can be optimized by chemical modifications and, in addition, further safety studies are necessary. Altogether, very interesting candidate compounds exist which have the potential to serve as starting points for the development of new immunosuppressive drugs.
format Online
Article
Text
id pubmed-9143092
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91430922022-05-29 Drug Candidates for Autoimmune Diseases Saurin, Sabrina Meineck, Myriam Erkel, Gerhard Opatz, Till Weinmann-Menke, Julia Pautz, Andrea Pharmaceuticals (Basel) Review Most of the immunosuppressive drugs used in the clinic to prevent organ rejection or to treat autoimmune disorders were originally isolated from fungi or bacteria. Therefore, in addition to plants, these are valuable sources for identification of new potent drugs. Many side effects of established drugs limit their usage and make the identification of new immunosuppressants necessary. In this review, we present a comprehensive overview of natural products with potent anti-inflammatory activities that have been tested successfully in different models of chronic inflammatory autoimmune diseases. Some of these candidates already have passed first clinical trials. The anti-inflammatory potency of these natural products was often comparable to those of established drugs, and they could be used at least in addition to standard therapy to reduce their dose to minimize unwanted side effects. A frequent mode of action is the inhibition of classical inflammatory signaling pathways, such as NF-κB, in combination with downregulation of oxidative stress. A drawback for the therapeutic use of those natural products is their moderate bioavailability, which can be optimized by chemical modifications and, in addition, further safety studies are necessary. Altogether, very interesting candidate compounds exist which have the potential to serve as starting points for the development of new immunosuppressive drugs. MDPI 2022-04-20 /pmc/articles/PMC9143092/ /pubmed/35631330 http://dx.doi.org/10.3390/ph15050503 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Saurin, Sabrina
Meineck, Myriam
Erkel, Gerhard
Opatz, Till
Weinmann-Menke, Julia
Pautz, Andrea
Drug Candidates for Autoimmune Diseases
title Drug Candidates for Autoimmune Diseases
title_full Drug Candidates for Autoimmune Diseases
title_fullStr Drug Candidates for Autoimmune Diseases
title_full_unstemmed Drug Candidates for Autoimmune Diseases
title_short Drug Candidates for Autoimmune Diseases
title_sort drug candidates for autoimmune diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143092/
https://www.ncbi.nlm.nih.gov/pubmed/35631330
http://dx.doi.org/10.3390/ph15050503
work_keys_str_mv AT saurinsabrina drugcandidatesforautoimmunediseases
AT meineckmyriam drugcandidatesforautoimmunediseases
AT erkelgerhard drugcandidatesforautoimmunediseases
AT opatztill drugcandidatesforautoimmunediseases
AT weinmannmenkejulia drugcandidatesforautoimmunediseases
AT pautzandrea drugcandidatesforautoimmunediseases